Heerspink, H. J. L., Sjöström, C. D., Inzucchi, S. E., Hallow, M. K., Cain, V. A., Rossing, P., . . . Sartipy, P. (2018). Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. Diabetes Obes Metab.

Heerspink, Hiddo J. L., C. David Sjöström, Silvio E. Inzucchi, Melissa K. Hallow, Valerie A. Cain, Peter Rossing, Bergur V. Stefansson, and Peter Sartipy. "Reduction in Albuminuria With Dapagliflozin Cannot Be Predicted By Baseline Clinical Characteristics or Changes in Most Other Risk Markers." Diabetes Obes Metab 2018.

Heerspink, Hiddo J. L., et al. "Reduction in Albuminuria With Dapagliflozin Cannot Be Predicted By Baseline Clinical Characteristics or Changes in Most Other Risk Markers." Diabetes Obes Metab 2018.